HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (“AUC”) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison.
The results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. More details can be found in the full press release at https://ibn.fm/ainxV.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The cleared indications for use for the HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment are available at https://www.heartbeam.com/indications.
The implications of this announcement are significant for emergency cardiac care. Chest pain is one of the most common reasons for emergency department visits, and rapid, accurate identification of heart attack risk is critical. Current diagnostic tools often require multiple tests and can lead to delays. A portable, credit card-sized device that provides immediate risk stratification could streamline triage, reduce unnecessary hospital admissions, and expedite treatment for those in need. The study's high AUC values indicate strong predictive performance, especially when a personal baseline ECG is available, suggesting that routine baseline recordings could enhance accuracy. This technology could eventually be used in primary care settings, urgent care clinics, or even by patients at home, potentially transforming how heart attacks are detected and managed.
For further updates on HeartBeam, visit the company's newsroom at https://ibn.fm/BEAT. This announcement contains forward-looking statements subject to risks and uncertainties as described in the company's SEC filings.
